Skip to content

GE HealthCare Technologies GEHC PDx — Acquisitions

Other segment segments

Imaging
$1.58B
AVS
$0
PCS
$0

Similar metrics at other companies

Thermo Fisher Scientific logo
TMOSpecialty Diagnostics — Acquisitions
$0
Thermo Fisher Scientific logo
TMOSpecialty Diagnostics — Purchases of property, plant and equipment
$35M+6.1%
Flowserve logo
FLSFPD — Acquisition(1)
$11.76M
Abbott logo
ABTDiagnostic Products — Additions to Property and Equipment
$128M-5.2%
Patrick Industries logo
PATKDistribution — Acquisitions
$2.75M
Revvity logo
RVTYDiagnostics — Goodwill, Acquisition
$0

Other financials

Income statement

See full
Revenue$5.1B+7.4%
Gross profit$2.0B-1.7%
Operating income$515.0M-18.1%
Net income$389.0M-31.0%
EPS (diluted)$0.85-30.9%

Balance sheet

See full
Total debt$10.6B+15.2%
Total equity$10.7B+16.1%
Total assets$37.1B+10.5%

Cash flow

See full
Operating cash flow$290.0M+16.0%
CapEx$178.0M+17.1%
Free cash flow$112.0M+14.3%

Valuation

See full
Market cap$29.91B-9.2%
P/E15.7×+1.0×
P/S1.4×-0.2×

Profitability

See full
Gross margin39.1%-2.9pp
Operating margin12.6%-1.1pp
Net margin9.1%-1.9pp
FCF margin7.2%

Returns & leverage

See full
Return on equity19.2%-7.1pp
Debt / equity0.0×
Current ratio1.2×+0.2×

Where this comes from

Reported directly by GE HealthCare Technologies in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.

The official record: GE HealthCare Technologies’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about GE HealthCare Technologies's pdx — acquisitions.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GE HealthCare Technologies's pdx — acquisitions?
GE HealthCare Technologies (GEHC) reported pdx — acquisitions of $0 in Q1 2026.
How has GE HealthCare Technologies's pdx — acquisitions changed year-over-year?
GE HealthCare Technologies's pdx — acquisitions decreased by 100.0% year-over-year, from $216M to $0.
What does pdx — acquisitions mean?
The total capital deployed by the Pharmaceutical Diagnostics segment to acquire other businesses, technologies, or product lines. This reflects the segment's commitment to inorganic growth and expansion of its diagnostic portfolio.